Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.54 |
| ▸ | CES2 | O00748 | 2/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | TLR2 | O60603 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25921526 | 1.00 | HTT (0.56) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL17738113 | 1.00 | HTT (0.56) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL21634574 | 0.98 | HTT (0.52) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL14759886 | 0.98 | EPHX1 (0.56) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL17479934 | 0.98 | EPHX1 (0.56) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL17479926 | 0.98 | EPHX1 (0.56) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL19418439 | 0.98 | EPHX1 (0.56) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL8378703 | 0.98 | EPHX1 (0.56) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL17479925 | 0.98 | EPHX1 (0.56) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL17479927 | 0.98 | EPHX1 (0.56) | HTTMEN1THRBKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295180-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295180-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295180-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | HTT 86/4885MEN1 2643/4885THRB 3558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.